Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML

医学 米多司他林 移植 内科学 Fms样酪氨酸激酶3 肿瘤科 造血干细胞移植 微小残留病 索拉非尼 髓系白血病 突变 白血病 生物 生物化学 肝细胞癌 基因
作者
Toshiki Terao,Ken‐ichi Matsuoka,Hiroko Ueda,Akifumi Matsumura,Chisato Matsubara,Kaho Kondo,Takumi Kondo,Hideaki Fujiwara,Noboru Asada,Daisuke Ennishi,Hisakazu Nishimori,Keiko Fujii,Nobuharu Fujii,Yoshinobu Maeda
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 3290-3291 被引量:5
标识
DOI:10.1182/blood-2022-163876
摘要

Introduction FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) and -tyrosine kinase domain (TKD) mutation were common mutations in acute myeloid leukemia (AML). FLT3-ITD mutation adversely affected the outcome of hematopoietic stem-cell transplantation (SCT). While sorafenib and midostaurin as maintenance therapy after SCT prolonged relapse-free and overall survival (OS), there are very few reports of post-transplant gilteritinib maintenance therapy outside of clinical trials. Hence, to explore the efficacy of the gilteritinib maintenance therapy post-SCT, we here report the prognostic impact of post-SCT gilteritinib maintenance in a clinical setting. Methods We retrospectively analyzed 25 FLT3-mutated relapsed or refractory AML patients who received allogeneic SCT at our center from January 1, 2011 to April 30, 2022. FLT3 mutation was analyzed by a commonly used polymerase chain reaction (PCR)-based assay. Measurable residual disease (MRD) was assessed by Wilms tumor 1 (WT1) mRNA expression in peripheral blood, and MRD positivity was defined as WT-1 >50 copies/μg in this study. Relapse was defined as an increase of 5% blasts or more. Non-relapse mortality (NRM) was defined as death without relapse. Leukemia-free survival (LFS) was defined as the time from transplantation to leukemia relapse or death from any cause, which comes first. OS was defined as the time from transplantation to death from any cause. Results The median age was 52 years. Twenty-two patients had ITD mutation and 5 had TKD mutation (2 had both ITD and TKD mutation). At the time of the transplant, 20 patients were in remission (6 were MRD-negative and 14 were MRD-positive) and five were in non-remission. All patients achieved hematologic complete remission (CR) after SCT and no patients relapsed within 30 days post-SCT. After hematological engraftment, 14 patients started to receive gilteritinib as maintenance therapy and 11 patients did not. Between the two groups, the patients' characteristics including disease status at transplant, SCT procedures, and donor sources were well balanced except for the administration of FLT3-inhibitor prior to SCT (100% in patients with gilteritinib maintenance and 45.5% in those without gilteritinib maintenance, p = 0.003). Eleven patients (78.6%) in the gilteritinib group and eight (72.7%) patients in the non-gilteritinib group had residual MRD in hematological CR or were non-CR prior to SCT. The median time from SCT to the initiation of gilteritinib was 36 days. The median dose at gilteritinib initiation was 40mg (range 20-120 mg). One patient developed grade 2 skin acute graft-versus-host disease (GVHD) after gilteritinib administration and 4/14 patients (28.6%) developed moderate-severe chronic GVHD (cGVHD, two developed pulmonary cGVHD, one eye and mouse, and one skin) with a median onset of 10.5 months (range 3.1-30.5 months), while only one patient temporary discontinued gilteritinib until the improvement of cGVHD. Late engraftment failure during gilteritinib maintenance was not observed. In terms of survival benefit, patients with gilteritinib maintenance showed significantly longer LFS and OS than those without gilteritinib (1-y LFS; 100% vs. 36.4%, 95% CI; 100-100% vs. 11.2-62.7%, p = 0.0028, Figure A, and 1-y OS; 100% vs. 45.5%, 95% CI; 100-100% vs. 16.7-70.7%, p = 0.0075, Figure B). The cumulative incidence of AML relapse at one-year in patients with gilteritinib maintenance group was significantly lower than those without (0% vs. 51.5%, 95% CI; 0-0% vs. 24.9-86.0%, p = 0.005). Especially, among patients with MRD positive or non-CR prior to SCT (n=19), patients who received gilteritinib maintenance showed a lower cumulative incidence of AML relapse at one-year than those without gilteritinib maintenance (0% vs. 68.8%, 95% CI; 0-0% vs. 35.9-95.2%, p = 0.0028, Figure C). Patients without MRD prior to SCT did not relapse with or without gilteritinib maintenance. These results suggest that gilteritinib maintenance therapy contributes to preventing post-transplant relapse in patients who remain MRD positive at the time of SCT. Conclusion Gilteritinib maintenance therapy post-SCT showed survival benefit in a clinical setting. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
落羽发布了新的文献求助10
刚刚
刚刚
cc完成签到,获得积分0
1秒前
募雨qaq发布了新的文献求助10
1秒前
啦啦啦完成签到,获得积分20
1秒前
1秒前
2秒前
思源的应助被elysia采纳,获得30
2秒前
2秒前
2秒前
2秒前
oosr发布了新的文献求助10
3秒前
3秒前
pp发布了新的文献求助10
3秒前
IceyCNZ发布了新的文献求助10
3秒前
初(*^▽^*)心的应助被哭泣冬瓜采纳,获得10
4秒前
酷波er的应助被檀兮尔采纳,获得10
4秒前
Czz发布了新的文献求助10
4秒前
5秒前
serena发布了新的文献求助20
5秒前
忧心的曼凝的应助被沧海云帆采纳,获得10
5秒前
QQ完成签到,获得积分10
5秒前
5秒前
Brian发布了新的文献求助10
5秒前
nn完成签到,获得积分10
6秒前
科研通AI6.4的应助被Wd采纳,获得10
6秒前
石心粥发布了新的文献求助10
6秒前
7秒前
爆米花的应助被MRCHONG采纳,获得10
7秒前
小马同学发布了新的文献求助10
7秒前
搜集达人的应助被坚定的问芙采纳,获得10
8秒前
年轻雁枫完成签到,获得积分10
8秒前
sun发布了新的文献求助10
8秒前
俊逸博超完成签到,获得积分10
8秒前
hhhhh完成签到,获得积分10
8秒前
周周周发布了新的文献求助10
8秒前
哭泣冬瓜完成签到,获得积分10
9秒前
星辰大海的应助被繁荣的尔风采纳,获得10
9秒前
IceyCNZ完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611